Treatment for anxiety
OwnerAndrew Tasker, Tracy Doucette +5inventors
InventorsAndrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.
Claims34
A method of treating, or delaying or inhibiting development of at least one sign or symptom of anxiety in, a patient having or at risk of developing symptoms of anxiety, comprising administering to the patient an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor, wherein the agent is a chimeric peptide comprising an active peptide linked to an internalization peptide, wherein the active peptide is either:
- a) a peptide consisting of 3-25 amino acids from the C-terminus of an NMDA receptor or
- b) a PDZ domain 1 and/or 2 from a PSD-95 receptor,
- wherein the patient is free of co-morbid stroke.
A method of treating, or delaying or inhibiting development of at least one sign or symptom of anxiety in, a patient suffering from or at risk of anxiety comprising administering to the patient an effective regime of a tSXV peptide linked to an internalization peptide, wherein the patient is free of co-morbid stroke.
Dependencies are inferred from the claim text.